Abstract |
The goal of this study was to characterize longitudinal changes in bone microarchitecture and function in women treated with an established antifracture therapeutic. In this double-blind, placebo-controlled pilot study, 53 early postmenopausal women with low bone density (age = 56 ± 4 years; femoral neck T-score = -1.5 ± 0.6) were monitored by high-resolution peripheral quantitative computed tomography (HR-pQCT) for 24 months following randomization to alendronate (ALN) or placebo (PBO) treatment groups. Subjects underwent annual HR-pQCT imaging of the distal radius and tibia, dual-energy X-ray absorptiometry (DXA), and determination of biochemical markers of bone turnover (BSAP and uNTx). In addition to bone density and microarchitecture assessment, regional analysis, cortical porosity quantification, and micro-finite- element analysis were performed. After 24 months of treatment, at the distal tibia but not the radius, HR-pQCT measures showed significant improvements over baseline in the ALN group, particularly densitometric measures in the cortical and trabecular compartments and endocortical geometry (cortical thickness and area, medullary area) (p < .05). Cortical volumetric bone mineral density (vBMD) in the tibia alone showed a significant difference between treatment groups after 24 months (p < .05); however, regionally, significant differences in Tb.vBMD, Tb.N, and Ct.Th were found for the lateral quadrant of the radius (p < .05). Spearman correlation analysis revealed that the biomechanical response to ALN in the radius and tibia was specifically associated with changes in trabecular microarchitecture (|ρ| = 0.51 to 0.80, p < .05), whereas PBO progression of bone loss was associated with a broad range of changes in density, geometry, and microarchitecture (|ρ| = 0.56 to 0.89, p < .05). Baseline cortical geometry and porosity measures best predicted ALN-induced change in biomechanics at both sites (ρ > 0.48, p < .05). These findings suggest a more pronounced response to ALN in the tibia than in the radius, driven by trabecular and endocortical changes.
|
Authors | Andrew J Burghardt, Galateia J Kazakia, Miki Sode, Anne E de Papp, Thomas M Link, Sharmila Majumdar |
Journal | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
(J Bone Miner Res)
Vol. 25
Issue 12
Pg. 2558-71
(Dec 2010)
ISSN: 1523-4681 [Electronic] United States |
PMID | 20564242
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
|
Copyright | Copyright © 2010 American Society for Bone and Mineral Research. |
Chemical References |
- Bone Density Conservation Agents
- Alendronate
|
Topics |
- Absorptiometry, Photon
- Alendronate
(administration & dosage, pharmacology, therapeutic use)
- Biomechanical Phenomena
- Bone Density
(drug effects)
- Bone Density Conservation Agents
(administration & dosage, pharmacology)
- Bone Remodeling
(drug effects)
- Bone and Bones
(diagnostic imaging, drug effects, physiology)
- Female
- Humans
- Longitudinal Studies
- Middle Aged
- Postmenopause
(drug effects)
- Radius
(diagnostic imaging, drug effects, physiology)
- Statistics, Nonparametric
- Tibia
(diagnostic imaging, drug effects, physiology)
- Time Factors
- Tomography, X-Ray Computed
- Treatment Outcome
|